As an important tool for detecting and diagnosing epilepsy, multi-channel EEG records the neuronal activities of different brain regions. Visual identification of abnormal EEG signals poses challenges, making the use of artificial intelligence techniques for automated seizure detection an inevitable trend. However, existing seizure detection methods often overlook the spatial relationship between EEG channels, which can't take full advantage of brain network structure. In this paper, we design an end-to-end spatiotemporal architecture for seizure detection based on Graph Convolutional Networks (GCN) and Bidirectional Gated Recurrent Units (BiGRU) to efficiently model the spatial dependence and temporal dynamics of EEG. Firstly, the original EEG signals are preprocessed by applying wavelet transform for temporal-frequency analysis. The Pearson correlation matrix is computed for specific frequency bands and GCN is utilized to extract spatial features between EEG channels. Then, these features are sent into the BiGRU network to capture temporal relationships. Finally, the detection decisions are achieved using fully connected layers and the multi-level decision rules are implemented to provide the final results. The proposed method is validated on CHB-MIT EEG dataset, achieving 98.85% sensitivity, 95.83% specificity, 97.35% accuracy, 97.4% F1-score, and 97.33% AUC. This network fusions multiple EEG characteristics in the spatial-temporal-frequency domains to improve the detection performance and the promising result demonstrates that the performance of this model is superior to or on par with existing methods.
Predicting drug-disease interactions (DDIs) is time-consuming and expensive. Improving the accuracy of prediction results is necessary, and it is crucial to develop a novel computing technology to predict new DDIs. The existing methods mostly use the construction of heterogeneous networks to predict new DDIs. However, the number of known interacting drug-disease pairs is small, so there will be many errors in this heterogeneous network that will interfere with the final results. A novel method, known as the dual-network L2,1-collaborative matrix factorization, is proposed to predict novel DDIs. The Gaussian interaction profile kernels and L2,1-norm are introduced in our method to achieve better results than other advanced methods. The network similarities of drugs and diseases with their chemical and semantic similarities are combined in this method. Cross validation is used to evaluate our method, and simulation experiments are used to predict new interactions using two different datasets. Finally, our prediction accuracy is better than other existing methods. This proves that our method is feasible and effective.
Epilepsy seizure prediction is vital for enhancing the quality of life for individuals with epilepsy. In this study, we introduce a novel hybrid deep learning architecture, merging DenseNet and Vision Transformer (ViT) with an attention fusion layer for seizure prediction. DenseNet captures hierarchical features and ensures efficient parameter usage, while ViT offers self-attention mechanisms and global feature representation. The attention fusion layer effectively amalgamates features from both networks, guaranteeing the most relevant information is harnessed for seizure prediction. The raw EEG signals were preprocessed using the short-time Fourier transform (STFT) to implement time–frequency analysis and convert EEG signals into time–frequency matrices. Then, they were fed into the proposed hybrid DenseNet–ViT network model to achieve end-to-end seizure prediction. The CHB-MIT dataset, including data from 24 patients, was used for evaluation and the leave-one-out cross-validation method was utilized to evaluate the performance of the proposed model. Our results demonstrate superior performance in seizure prediction, exhibiting high accuracy and low redundancy, which suggests that combining DenseNet, ViT, and the attention mechanism can significantly enhance prediction capabilities and facilitate more precise therapeutic interventions.
Electroencephalography (EEG) records the electrical activity of the brain, which is an important tool for the automatic detection of epileptic seizures. It is certainly a very heavy burden to only recognize EEG epilepsy manually, so the method of computer-assisted treatment is of great importance. This paper presents a seizure detection algorithm based on variational modal decomposition (VMD) and a deep forest (DF) model. Variational modal decomposition is performed on EEG recordings, and the first three variational modal functions (VMFs) are selected to construct the time–frequency distribution of the EEG signals. Then, the log−Euclidean covariance matrix (LECM) is computed to represent the EEG properties and form EEG features. The deep forest model is applied to complete the EEG signal classification, which is a non-neural network deep model with a cascade structure that performs feature learning through the forest. In addition, to improve the classification accuracy, postprocessing techniques are performed to generate the discriminant results by moving average filtering and adaptive collar expansion. The algorithm was evaluated on the Bonn EEG dataset and the Freiburg long−term EEG dataset, and the former achieved a sensitivity and specificity of 99.32% and 99.31%, respectively. The mean sensitivity and specificity of this method for the 21 patients in the Freiburg dataset were 95.2% and 98.56%, respectively, with a false detection rate of 0.36/h. These results demonstrate the superior performance advantage of our algorithm and indicate its great research potential in epilepsy detection.
21 October 2019 in IEEE Journal of Biomedical and Health Informatics
In recent years, with the diversity and variability of cancer information, the multi-omics data have been applied in various fields. A lot of existing models of principal component analysis can only process single data, which makes limitations on cancer research. Therefore, in this paper, a new model called integrative principal component analysis (IPCA) is proposed to achieve the unification of multi-omics data. In addition, in order to preserve the high-order manifold structure between the data, an integrative hypergraph regularized principal component analysis (IHPCA) is further proposed by applying the hypergraph regularized constraint. The effectiveness of IHPCA method is tested on three multi-omics datasets. Experimental results show that the proposed method has better performance than other representative methods on sample clustering and common expression genes (co-expression genes) network analysis.
With the development of research on the complex aetiology of many diseases, computational drug repositioning methodology has proven to be a shortcut to costly and inefficient traditional methods. Therefore, developing more promising computational methods is indispensable for finding new candidate diseases to treat with existing drugs. In this paper, a model integrating a new variant of message passing neural network and a novel-gated fusion mechanism called GLGMPNN is proposed for drug–disease association prediction. First, a light-gated message passing neural network (LGMPNN), including message passing, aggregation and updating, is proposed to separately extract multiple pieces of information from the similarity networks and the association network. Then, a gated fusion mechanism consisting of a forget gate and an output gate is applied to integrate the multiple pieces of information to extent. The forget gate calculated by the multiple embeddings is built to integrate the association information into the similarity information. Furthermore, the final node representations are controlled by the output gate, which fuses the topology information of the networks and the initial similarity information. Finally, a bilinear decoder is adopted to reconstruct an adjacency matrix for drug–disease associations. Evaluated by 10-fold cross-validations, GLGMPNN achieves excellent performance compared with the current models. The following studies show that our model can effectively discover novel drug–disease associations.